The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.
Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...
A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...
On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...
If you’ve been diagnosed with major depressive disorder, seasonal affective depression or any other type of depression, your ...